Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib and Tamoxifen in Metastatic Breast Cancer
NCT00052728Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose, Recommended Phase II Dose and 4 more. Started Dec 2002; status: completed.
02
Drugs
tipifarnib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00052728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052728.